<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Myopathies of systemic disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Myopathies of systemic disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Myopathies of systemic disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Lacomis, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeremy M Shefner, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John F Dashe, MD, PhD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 08, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skeletal muscle is a complex tissue that is composed of many structural proteins and several energy-producing pathways. Thus, it can be perturbed by a number of systemic disorders.
        </p>
        <p>
         This topic will review the myopathies associated with endocrine disease, malabsorption, electrolyte disturbance, critical illness, and rheumatic disease.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ENDOCRINE MYOPATHIES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Endocrine diseases are generally associated with hormonally mediated systemic alterations in metabolism. At any time during the course of many endocrinopathies, muscle may become affected. The diagnosis of such a myopathy may be more difficult if it is the presenting manifestation of the endocrinopathy.
        </p>
        <p class="headingAnchor" id="H881749651">
         <span class="h2">
          Adrenal insufficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Severe, subjective, generalized weakness has been described in up to 100 percent of patients with Addison disease [
         <a href="#rid1">
          1,2
         </a>
         ]. Cramping and fatigue may also occur. Some patients develop lower extremity flexion contractures and myalgias as their primary complaints [
         <a href="#rid3">
          3,4
         </a>
         ]. Symptoms improve with the administration of glucocorticoids. (See
         <a class="medical medical_review" href="/z/d/html/159.html" rel="external">
          "Clinical manifestations of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p>
         Adequate clinicopathologic studies are lacking; therefore, it is difficult to clearly categorize the weakness as myopathic.
        </p>
        <p>
         The mechanism of adrenal insufficiency-associated weakness is not established, but potential causes include changes in carbohydrate metabolism and electrolyte abnormalities (hyponatremia and hyperkalemia), a loss of exercise-induced glycogenolysis, and circulatory insufficiency [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3514401234">
         <span class="h2">
          Cushing syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Muscle weakness is a common accompaniment of all types of hypercortisolism, both endogenous (Cushing syndrome and Cushing disease) and exogenous. The clinical features are similar in all of the cortisol excess states. (See
         <a class="medical medical_review" href="/z/d/html/143.html" rel="external">
          "Epidemiology and clinical manifestations of Cushing syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5171.html" rel="external">
          "Glucocorticoid-induced myopathy"
         </a>
         .)
        </p>
        <p>
         Muscle weakness in Cushing syndrome may be due to glucocorticoid-induced inhibition of protein synthesis with impairment in ribosome function [
         <a href="#rid6">
          6
         </a>
         ]. Accelerated protein catabolism [
         <a href="#rid7">
          7
         </a>
         ], changes in amino acid export from muscle [
         <a href="#rid8">
          8
         </a>
         ], and alteration of carbohydrate metabolism [
         <a href="#rid5">
          5
         </a>
         ] are all likely to play a role. Altered gene regulation and cell signaling by steroid hormones probably leads to some of these metabolic changes [
         <a href="#rid9">
          9
         </a>
         ]. In particular, the forkhead box O3a promoter is upregulated along with atrogin-1 and muscle-ring finger protein-1 [
         <a href="#rid10">
          10
         </a>
         ]. There is also enhanced protein turnover mediated by the ubiquitin-proteosome proteolytic pathway, which is stimulated by glucocorticoids [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Clinically, weakness with atrophy occurs insidiously in 50 to 90 percent of patients with Cushing syndrome [
         <a href="#rid12">
          12,13
         </a>
         ]. Patients usually have other physical features of hypercortisolism such as "moon facies." The weakness, which may or may not be accompanied by myalgias, is proximal in distribution, first affecting the lower extremities and then the upper extremities. Facial and bulbar muscles are generally not involved, and diaphragm weakness occurs rarely. This respiratory involvement can be severe, however [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         On laboratory evaluation, the serum CK is normal. In fact, the serum CK and myoglobin are low when compared with controls [
         <a href="#rid15">
          15
         </a>
         ]. Electromyography is sometimes normal, but some short-duration, low-amplitude motor unit potentials, compatible with myopathy, are often detected. Occasionally, insertional activity is increased [
         <a href="#rid16">
          16,17
         </a>
         ].
        </p>
        <p>
         The major histologic finding is atrophy of type 2 muscle fibers [
         <a href="#rid18">
          18
         </a>
         ], especially type 2B (high glycolytic, low oxidative potential) muscle fibers.
        </p>
        <p>
         Patients generally improve over months with treatment of the endocrinopathy [
         <a href="#rid14">
          14,17
         </a>
         ]. The greatest improvement occurs within three months, but strength and muscle mass may continue to increase for over a year. Improvement may be incomplete [
         <a href="#rid19">
          19,20
         </a>
         ].
        </p>
        <p>
         The treatment of Cushing syndrome depends on the etiology; options include pituitary or adrenal tumor removal, medical therapy to reduce hypothalamic corticotropin-releasing hormone, and chemical adrenalectomy. Physical therapy may be helpful [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/174.html" rel="external">
          "Overview of the treatment of Cushing syndrome"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2320994673">
         <span class="h2">
          Diabetic muscle infarction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Diabetic muscle infarction is a rare disorder that affects patients who have relatively longstanding diabetes, many of whom have other micro- or macrovascular complications. Clinical manifestations include acute or subacute onset of muscle pain, swelling, and associated tenderness. The muscles of the thigh and calf are most commonly affected. Frequent but nonspecific laboratory findings include elevation of plasma CK enzyme activity, leukocytosis, and elevated erythrocyte sedimentation rate (ESR).
        </p>
        <p>
         Diabetic muscle infarction is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/5135.html" rel="external">
          "Diabetic muscle infarction"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H735983134">
         <span class="h2">
          Hyperaldosteronism with myopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Weakness is a very common complaint in patients with hyperaldosteronism [
         <a href="#rid22">
          22
         </a>
         ], and it has been ascribed to potassium deficiency [
         <a href="#rid23">
          23
         </a>
         ]. On the other hand, objective weakness is rare and in one report was seen in only 1 of 12 patients [
         <a href="#rid23">
          23
         </a>
         ]. Other reported features include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a study describing two patients with hyperaldosteronism and myopathy, serum CK levels were elevated in both, and the electromyography findings were "myopathic" in one [
         <a href="#rid24">
          24
         </a>
         ]. Electron microscopy revealed dilatation of the T-tubule system and sarcoplasmic reticulum. Muscle strength improved with treatment of the underlying condition.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rhabdomyolysis from hypokalemia was a presenting manifestation of hyperaldosteronism in a 40-year-old woman [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Activity-dependent conduction block was identified in a patient with acute weakness and hyperaldosteronism [
         <a href="#rid26">
          26
         </a>
         ]. This conduction block may contribute to weakness and paralysis in patients with hypokalemia and hyperaldosteronism.
        </p>
        <p>
        </p>
        <p>
         The general clinical features and treatment of primary aldosteronism are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/140.html" rel="external">
          "Pathophysiology and clinical features of primary aldosteronism"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/141.html" rel="external">
          "Treatment of primary aldosteronism"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1039402001">
         <span class="h2">
          Hyperparathyroid myopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The insidious development of proximal weakness (legs involved more than arms), fatigue, musculoskeletal pain, and hyperreflexia has been reported in approximately 25 percent of patients with primary hyperparathyroidism [
         <a href="#rid27">
          27,28
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2031.html" rel="external">
          "Primary hyperparathyroidism: Clinical manifestations"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2029.html" rel="external">
          "Primary hyperparathyroidism: Diagnosis, differential diagnosis, and evaluation"
         </a>
         .)
        </p>
        <p>
         Patients with secondary hyperparathyroidism may be similarly affected, but a coexistent neuropathy is usually present [
         <a href="#rid5">
          5
         </a>
         ]. Some patients with secondary hyperparathyroidism also have osteomalacia, which alone is commonly associated with myopathy. (See
         <a class="local">
          'Osteomalacic myopathy and celiac sprue'
         </a>
         below.)
        </p>
        <p>
         Rarely, a malignant necrotizing myopathy with vascular calcifications occurs in patients with hyperparathyroidism and uremia [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         On laboratory testing, serum calcium, alkaline phosphatase, and parathyroid hormone (PTH) are elevated, while the serum CK is normal. Electromyography findings are mixed and include short-duration, low-amplitude motor unit potentials as well as high-amplitude, long-duration motor unit potentials [
         <a href="#rid30">
          30-32
         </a>
         ]. Limited reports of nerve conduction studies have been normal. Histopathologic studies of muscle reveal mostly atrophy of type 2 more than type 1 fibers.
        </p>
        <p>
         The pathogenesis of hyperparathyroid myopathy is uncertain. There may be a neuronal or motor axonal component. Increased regulators of calcium homeostasis, namely PTH and vitamin D, may be important in inducing weakness [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Patients usually regain strength within weeks of treatment of the endocrinopathy [
         <a href="#rid32">
          32,33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2065.html" rel="external">
          "Primary hyperparathyroidism: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3970307902">
         <span class="h2">
          Hyperthyroid myopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Muscle weakness with or without atrophy and myalgias occurs in 60 to 80 percent of patients with untreated hyperthyroidism. This discussion will briefly review hyperthyroid myopathy. A more detailed discussion is found separately. (See
         <a class="medical medical_review" href="/z/d/html/4836.html" rel="external">
          "Neurologic manifestations of hyperthyroidism and Graves' disease", section on 'Myopathy'
         </a>
         .)
        </p>
        <p>
         Cramps are less common than with hypothyroidism. Patients with hyperthyroidism tend to develop muscle involvement more frequently after the age of 40. The likelihood of developing weakness, but not its degree, is correlated with the duration of the hyperthyroid state.
        </p>
        <p>
         Approximately two-thirds of patients with hyperthyroid myopathy report proximal weakness that usually begins several weeks to several months after the onset of hyperthyroidism. Hip flexors and quadriceps may be predominantly affected. The remainder has distal as well as proximal muscle involvement. Bulbar and respiratory muscle dysfunction occurs rarely. Weakness is sometimes the sole manifestation of the endocrinopathy. Myalgias may occur. Deep tendon reflexes are normal or increased, an unusual finding in a myopathic disorder. Paresthesias, due to coexisting polyneuropathy, may be present.
        </p>
        <p>
         Laboratory testing usually shows a normal serum CK level; electromyography sometimes reveals "myopathic" motor unit potentials, but fibrillation potential activity is usually absent. Pathologic changes are typically nonspecific.
        </p>
        <p>
         Treatment involves returning the patient to euthyroidism. Patients generally improve fully within four months.
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Hypothyroid myopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Muscle disease is a common complication of congenital and adult-onset hypothyroidism. Hypothyroid myopathy is briefly reviewed here and is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4837.html" rel="external">
          "Hypothyroid myopathy"
         </a>
         .)
        </p>
        <p>
         Patients with hypothyroidism frequently complain of weakness with or without cramps and myalgias. Patients of all ages and either sex may be affected, but hypothyroidism and therefore hypothyroid myopathy is more common in women. Weakness may be an initial symptom of hypothyroidism, or it may occur years into the course of the endocrinopathy.
        </p>
        <p>
         Myopathic weakness in congenital hypothyroidism occurs in association with other manifestations of cretinism, is accompanied by prominent muscle hypertrophy, and responds to thyroid replacement. (See
         <a class="medical medical_review" href="/z/d/html/4837.html" rel="external">
          "Hypothyroid myopathy", section on 'Congenital hypothyroidism'
         </a>
         .)
        </p>
        <p>
         In adults, the severity of muscle disease can range from asymptomatic elevation of serum creatine kinase (CK) to disabling muscle weakness. In addition to proximal muscle weakness, neurologic findings include sluggish or hung-up reflexes, myoedema (expansion of muscle following direct percussion), and, rarely, an increase in muscle bulk. In chronic hypothyroid myopathy, the triad of muscle hypertrophy, weakness, and CK elevation may occur. Rhabdomyolysis has been reported but occurs rarely. Myopathy attributed to hypothyroidism induced by the immune checkpoint inhibitor
         <a class="drug drug_general" data-topicid="98764" href="/z/d/drug information/98764.html" rel="external">
          nivolumab
         </a>
         was also reported [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4837.html" rel="external">
          "Hypothyroid myopathy", section on 'Clinical and laboratory manifestations'
         </a>
         .)
        </p>
        <p>
         The presence of typical myopathic symptoms in the setting of hypothyroidism is sufficient to make the diagnosis. Electromyography is normal or shows myopathic changes. Muscle biopsy, if performed to exclude other conditions, shows nonspecific changes and only mild, if any, inflammation. (See
         <a class="medical medical_review" href="/z/d/html/4837.html" rel="external">
          "Hypothyroid myopathy", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
         Thyroid replacement usually leads to resolution of laboratory abnormalities and symptoms over a few to several weeks. Weakness may recover more slowly, over several months, and, in severely affected patients, may persist even longer. Pathologic changes in muscle may also persist after clinical recovery occurs. (See
         <a class="medical medical_review" href="/z/d/html/4837.html" rel="external">
          "Hypothyroid myopathy", section on 'Treatment and prognosis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          MYOPATHIES ASSOCIATED WITH MALABSORPTION
         </span>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Osteomalacic myopathy and celiac sprue
         </span>
         <span class="headingEndMark">
          —
         </span>
         Myopathy is common in osteomalacia, and proximal-predominant weakness is the initial symptom in approximately 30 percent of cases [
         <a href="#rid35">
          35
         </a>
         ]. Patients often have pain, which may be partly of myopathic and partly of bone origin.
        </p>
        <p>
         Celiac sprue can present with osteomalacic myopathy [
         <a href="#rid36">
          36,37
         </a>
         ]. Although neuropathies with or without ataxia are more common accompaniments of sprue, myopathy can be the primary neuromuscular presentation [
         <a href="#rid38">
          38
         </a>
         ]. Histopathologic features may include muscle inflammation, suggesting an autoimmune component.
        </p>
        <p>
         Patients who develop malabsorption after gastric bypass can also develop vitamin D deficiency [
         <a href="#rid39">
          39,40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2045.html" rel="external">
          "Epidemiology and etiology of osteomalacia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4774.html" rel="external">
          "Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/587.html" rel="external">
          "Bariatric surgery: Postoperative nutritional management"
         </a>
         .)
        </p>
        <p>
         Patients typically have malabsorption with hypovitaminosis D, secondary hyperparathyroidism, and, eventually, bony abnormalities (pseudofractures). An elevation in serum alkaline phosphatase is a clue to diagnosis. The 25-dihydroxyvitamin D3 level is low, but 1,25-dihydroxyvitamin D3 may be normal if there is increased renal conversion of vitamin D to the dihydroxy form in the setting of hypophosphatemia and elevated parathyroid hormone (PTH) [
         <a href="#rid41">
          41,42
         </a>
         ]. The serum creatine kinase (CK) level is usually normal. Electromyography findings may be normal or may show some mild "myopathic" motor unit potential changes without fibrillation potentials.
        </p>
        <p>
         Histopathologic findings are nonspecific but may include type 2 muscle fiber atrophy [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
         It is important to identify the underlying cause of osteomalacia so that the disorder can be corrected. Vitamin D and calcium supplementation are typically beneficial over a period of months [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2040.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of osteomalacia in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h2">
          Vitamin E deficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">
          Vitamin E
         </a>
         is fat soluble and can be depleted in malabsorption states. Patients with celiac sprue and patients who have undergone gastric bypass surgery may be especially at risk. (See
         <a class="medical medical_review" href="/z/d/html/2582.html" rel="external">
          "Overview of vitamin E", section on 'Deficiency'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4774.html" rel="external">
          "Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/587.html" rel="external">
          "Bariatric surgery: Postoperative nutritional management"
         </a>
         .)
        </p>
        <p>
         Neurologic complications of
         <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">
          vitamin E
         </a>
         deficiency include ataxia and peripheral neuropathy, but also myoclonus, dementia, epilepsy, and myopathy. In particular, a vacuolar myopathy with inflammation can be a consequence, although it is uncommon. Serum CK may be normal [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">
          Vitamin E
         </a>
         supplementation and a gluten-free diet benefit celiac sprue patients who have vitamin E deficiency with neuropathy and myopathy. The myopathic component improves over a few months, and histologic improvement on muscle biopsy has also been reported [
         <a href="#rid43">
          43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/4777.html" rel="external">
          "Management of celiac disease in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          HYPOKALEMIC MYOPATHY
         </span>
         <span class="headingEndMark">
          —
         </span>
         A vacuolar myopathy occurs in patients with repeated bouts of hypokalemic periodic paralysis.
        </p>
        <p>
         Paralysis from severe hypokalemia can also occur in some clinical settings, including chronic diarrhea, renal tubular acidosis, primary aldosteronism, and alcoholism. Certain drug and substance intoxications, from licorice, cola, and clay, for example, can also trigger this phenomenon [
         <a href="#rid44">
          44-47
         </a>
         ].
        </p>
        <p>
         Weakness associated with hypokalemia can develop over hours to days, and usually affects proximal muscles. It may be associated with cramping. Rarely, the diaphragm, cranial, or posterior cervical muscles are affected [
         <a href="#rid48">
          48
         </a>
         ]. Tendon reflexes may be diminished, and cardiac arrhythmias can also occur.
        </p>
        <p>
         Muscle membrane may become unexcitable and, eventually, myofiber vacuolation and necrosis can occur. The CK may be normal or slightly elevated. Electromyography may show "myopathic" motor unit potentials, which may be accompanied by fibrillation potentials.
        </p>
        <p>
         Administration of potassium is the appropriate treatment. Depending on the acuity and severity, intravenous verses oral replacement should be considered. Improvement begins over an hour or two, but patients with severe weakness may take weeks to improve.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h1">
          MYOPATHY ASSOCIATED WITH CRITICAL ILLNESS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neuromuscular weakness related to critical illness is reviewed here briefly and discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5144.html" rel="external">
          "Neuromuscular weakness related to critical illness"
         </a>
         .)
        </p>
        <p>
         In the setting of critical illness, the most common causes of neuromuscular weakness are critical illness myopathy (CIM), critical illness polyneuropathy (CIP), or a combination of the two. Risk factors include sepsis, multiorgan failure, and the systemic inflammatory response syndrome. The use of intravenous glucocorticoids is another possible risk factor for CIM.
        </p>
        <p>
         Typical features of CIM and CIP include symmetric, flaccid limb weakness, which is usually worse in proximal compared with distal muscles. Extraocular muscles are relatively spared, and facial muscles are usually but not always spared. The diagnosis is suspected in patients who develop flaccid muscle weakness and ventilatory failure after the onset of critical illness. In the appropriate setting, the diagnosis is confirmed when other, unrelated causes of weakness are excluded or deemed unlikely.
        </p>
        <p>
         Treatment of both CIM and CIP is directed toward aggressive management of medical conditions, avoidance of additional complications such as venous thrombosis, and rehabilitation. Minimizing sedation and early mobilization of critically ill patients may help to prevent or mitigate neuromuscular weakness.
        </p>
        <p>
         Many patients who survive critical illness experience prolonged impairment in cognition, mental health, and physical function, known as post-intensive care syndrome (PICS). Neuromuscular weakness related to critical illness is often a significant aspect of this syndrome. In survivors of CIP with mild or moderate nerve injury, recovery of muscle strength generally occurs over weeks to months. Patients with severe CIP may remain quadriplegic. Patients with CIM tend to have better outcomes than those with CIP.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h1">
          MYOPATHIES IN RHEUMATIC DISEASES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Muscle weakness and inflammation are characteristic features of inflammatory myopathies. In addition, skeletal muscle can be affected by polymyalgia rheumatica (PMR), vasculitis, or amyloidosis.
        </p>
        <p class="headingAnchor" id="H1893841483">
         <span class="h2">
          Amyloid myopathy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Amyloid myopathy is rare, but it may be underdiagnosed unless muscle biopsy specimens are routinely evaluated by Congo red stain with fluorescence optics [
         <a href="#rid49">
          49,50
         </a>
         ]. It occurs most often in the setting of systemic amyloidosis, but approximately one-quarter of cases may occur in isolation (ie, isolated amyloid myopathy) [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         Patients with amyloid myopathy usually have proximal weakness and an elevated serum CK level. Less than half of patients have dysphagia, myalgias, or enlarged muscles with or without macroglossia [
         <a href="#rid52">
          52
         </a>
         ]. Relatively uncommon features include distal weakness, muscle atrophy, focal axial myopathy [
         <a href="#rid53">
          53
         </a>
         ], respiratory dysfunction, claudication, and exercise intolerance with or without rhabdomyolysis [
         <a href="#rid51">
          51,54
         </a>
         ].
        </p>
        <p>
         Systemic features may include bruising, diarrhea, autonomic neuropathy, renal and cardiac dysfunction, and arthropathy [
         <a href="#rid49">
          49,55
         </a>
         ]. Magnetic resonance imaging (MRI) may identify distinctive reticulation of the subcutaneous fat [
         <a href="#rid55">
          55,56
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/122846.html" rel="external">
          "Cardiac amyloidosis: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
         The mean or median age at diagnosis is 60 to 67 years, but there is a wide range, and patients with isolated amyloid myopathy tend to be younger [
         <a href="#rid51">
          51
         </a>
         ]. The mean time to diagnosis is 22 months, reflecting the difficulty in recognition [
         <a href="#rid52">
          52,54
         </a>
         ]. The clinical, laboratory, and electrodiagnostic features may mimic an inflammatory myopathy. Patients with immunoglobulin light chain (AL) amyloid myopathy may have elevated cardiac troponin T levels, even in the absence of other features of cardiac disease [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         Nerve conduction studies may reveal low peroneal or tibial motor amplitudes [
         <a href="#rid57">
          57
         </a>
         ]. Needle examination features include short-duration motor unit potentials in all cases, and long-duration motor unit potentials mainly in distal muscles in a minority [
         <a href="#rid49">
          49,57
         </a>
         ]. At least half exhibit fibrillation potentials [
         <a href="#rid49">
          49,57
         </a>
         ]. Complex repetitive or myotonic discharges are uncommonly encountered [
         <a href="#rid57">
          57
         </a>
         ]. There may be evidence of a coexisting axonal sensorimotor polyneuropathy or mononeuropathy such as carpal tunnel syndrome.
        </p>
        <p>
         Pathologically, there is amyloid deposition around small blood vessels, encasement of muscle fibers by amyloid, and mild muscle fiber necrosis and regeneration  (
         <a class="graphic graphic_picture graphicRef97036" href="/z/d/graphic/97036.html" rel="external">
          picture 1
         </a>
         ). Mild signs of denervation atrophy may be present, and inflammatory infiltrates are uncommon [
         <a href="#rid49">
          49,54
         </a>
         ].
        </p>
        <p>
         Most patients with amyloid myopathy have AL amyloidosis with or without multiple myeloma (see
         <a class="medical medical_review" href="/z/d/html/6665.html" rel="external">
          "Monoclonal immunoglobulin deposition disease"
         </a>
         ). Tissue biopsy should be used to confirm the diagnosis in all cases of amyloidosis. (See
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Diagnosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6668.html" rel="external">
          "Clinical presentation, laboratory manifestations, and diagnosis of immunoglobulin light chain (AL) amyloidosis"
         </a>
         .)
        </p>
        <p>
         Some patients with amyloid myopathy have familial amyloidosis with mutations in gelsolin [
         <a href="#rid49">
          49
         </a>
         ] and transthyretin [
         <a href="#rid58">
          58,59
         </a>
         ]. Transthyretin gene mutations are typically associated with distal weakness and polyneuropathy [
         <a href="#rid58">
          58
         </a>
         ], and age of onset may be earlier in familial forms (see
         <a class="medical medical_review" href="/z/d/html/5590.html" rel="external">
          "Genetic factors in the amyloid diseases"
         </a>
         ). Isolated amyloid myopathy may be the initial presentation of systemic amyloidosis [
         <a href="#rid60">
          60
         </a>
         ] but most often is associated with limb-girdle muscular dystrophy types LGMD R12 (anoctamin 5-related) or LGMD R2 (dysferlin-related) [
         <a href="#rid51">
          51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6190.html" rel="external">
          "Limb-girdle muscular dystrophy", section on 'Anoctaminopathies'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6190.html" rel="external">
          "Limb-girdle muscular dystrophy", section on 'Dysferlinopathies'
         </a>
         .)
        </p>
        <p>
         The prognosis is poor for most forms of amyloidosis, but treatments for transthyretin amyloid are now available (see
         <a class="medical medical_review" href="/z/d/html/5589.html" rel="external">
          "Overview of amyloidosis", section on 'Treatment'
         </a>
         ). A minority of AL amyloidosis patients treated with alkylating agents, usually
         <a class="drug drug_general" data-topicid="9605" href="/z/d/drug information/9605.html" rel="external">
          melphalan
         </a>
         , respond [
         <a href="#rid55">
          55
         </a>
         ], and mean survival is 22 months [
         <a href="#rid54">
          54
         </a>
         ]. The role of more aggressive immunotherapies and stem cell transplant in treating amyloid myopathy is undetermined [
         <a href="#rid54">
          54
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6666.html" rel="external">
          "Treatment and prognosis of immunoglobulin light chain (AL) amyloidosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4151298700">
         <span class="h2">
          Inflammatory myopathies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dermatomyositis
         </strong>
         and
         <strong>
          polymyositis
         </strong>
         – These myopathies may occur in the setting of systemic connective tissue diseases, and less often in association with malignancy. These disorders are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14918.html" rel="external">
          "Pathogenesis of inflammatory myopathies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5159.html" rel="external">
          "Clinical manifestations of dermatomyositis and polymyositis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5162.html" rel="external">
          "Malignancy in dermatomyositis and polymyositis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inclusion body myositis
         </strong>
         – This disorder occasionally occurs in patients with Sjögren's disease. This disorder is also discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5163.html" rel="external">
          "Clinical manifestations and diagnosis of inclusion body myositis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5164.html" rel="external">
          "Management of inclusion body myositis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Necrotizing myopathy
         </strong>
         – This may occur in several settings, including in association with 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR) and signal recognition particle (SRP) antibodies, as a paraneoplastic disorder or rarely with the use of certain drugs (eg, checkpoint inhibitor immunotherapy, statins). (See
         <a class="medical medical_review" href="/z/d/html/96368.html" rel="external">
          "Toxicities associated with immune checkpoint inhibitors", section on 'Rheumatologic and musculoskeletal'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5190.html" rel="external">
          "Paraneoplastic syndromes affecting spinal cord, peripheral nerve, and muscle", section on 'Acute necrotizing myopathy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Viral infection and myopathy
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         HIV myopathy can be a presenting manifestation of HIV infection or can occur in the later stages of infection. (See
         <a class="medical medical_review" href="/z/d/html/15653.html" rel="external">
          "Diagnosis and differential diagnosis of dermatomyositis and polymyositis in adults", section on 'Differential diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Myopathy may accompany other viral disorders including coronavirus disease 2019 (COVID-19). (See
         <a class="medical medical_review" href="/z/d/html/128153.html" rel="external">
          "COVID-19: Neurologic complications and management of neurologic conditions", section on 'Other acute neuromuscular syndromes'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Polymyalgia rheumatica
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with PMR typically are over 50 years of age and have bilateral aching and stiffness in proximal muscles, hips, neck, or torso. The stiffness is usually noted in the morning. It is often difficult to determine whether there is proximal muscle weakness because the examination is limited by pain. The pain usually worsens with activity. Imaging studies suggest inflammation in synovial tissues. Systemic features are common, including anorexia, weight loss, and fatigue (see
         <a class="medical medical_review" href="/z/d/html/8235.html" rel="external">
          "Clinical manifestations and diagnosis of polymyalgia rheumatica"
         </a>
         ). The RS3PE (Remitting, Symmetric, Seronegative [for rheumatoid arthritis] Synovitis with Pitting Edema) syndrome may be considered a variant of PMR when it responds to low-dose
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         . It may also be associated with neoplastic disorders or other rheumatic diseases. These patients may also present with "weakness" due to pain. (See
         <a class="medical medical_review" href="/z/d/html/8235.html" rel="external">
          "Clinical manifestations and diagnosis of polymyalgia rheumatica"
         </a>
         .)
        </p>
        <p>
         In addition, some patients with PMR develop giant cell arteritis of the head and neck, potentially leading to headache, jaw claudication, anterior ischemic optic neuropathy, aortic aneurysm, cranial neuropathy, and even brachial plexopathy and stroke. (See
         <a class="medical medical_review" href="/z/d/html/8225.html" rel="external">
          "Clinical manifestations of giant cell arteritis"
         </a>
         .)
        </p>
        <p>
         Typically, elevations in Westergren erythrocyte sedimentation rate (ESR; &gt;40 mm/hour) and C-reactive protein are present. The serum creatine kinase (CK) level is normal. (See
         <a class="medical medical_review" href="/z/d/html/8235.html" rel="external">
          "Clinical manifestations and diagnosis of polymyalgia rheumatica"
         </a>
         .)
        </p>
        <p>
         Electromyography is also normal. Muscle histopathology is either normal or reveals atrophy of type 2 muscle fibers [
         <a href="#rid61">
          61,62
         </a>
         ]. Microvascularization of muscle has also been reported [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
         There is usually a dramatic improvement with low doses of
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/8222.html" rel="external">
          "Treatment of polymyalgia rheumatica"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h2">
          Skeletal muscle vasculitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skeletal muscle vasculitis typically occurs in association with either systemic vasculitis or isolated peripheral nervous system vasculitis. In either group, an associated vasculitic neuropathy is often the major peripheral nervous system clinical manifestation.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Approximately 55 percent or more of patients with vasculitis affecting skeletal muscle have substantial myalgias and some degree of weakness. They may also exhibit weight loss and fever, and some (approximately 20 percent in one series) will have paresthesias due to an associated peripheral neuropathy [
         <a href="#rid64">
          64
         </a>
         ]. Patients with systemic vasculitides may also have fever, arthralgias, and involvement of other organ systems.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In polyarteritis nodosa, vascular occlusions and aneurysmal dilatations can affect digits and intra-abdominal organs. Skeletal muscle MRI with contrast may show small, fluffy enhancing lesions centered on blood vessels in addition to signal changes of muscle edema [
         <a href="#rid65">
          65
         </a>
         ]. Other systemic vasculitides that may involve skeletal muscle include eosinophilic granulomatosis with polyangiitis (EGPA, Churg-Strauss), granulomatosis with polyangiitis, hypersensitivity vasculitis, and microscopic polyarteritis [
         <a href="#rid66">
          66-68
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8226.html" rel="external">
          "Overview of and approach to the vasculitides in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Occasionally, patients with systemic lupus erythematosus, rheumatoid arthritis, scleroderma, HIV infection, and Sjögren's disease can develop skeletal muscle vasculitis, often in conjunction with a vasculitic peripheral neuropathy. MRI may reveal increased signal on slow tau inversion recovery (STIR) sequences in affected muscles [
         <a href="#rid69">
          69
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8236.html" rel="external">
          "Clinical manifestations and diagnosis of vasculitic neuropathies"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Giant cell arteritis is only rarely associated with skeletal muscle vasculitis [
         <a href="#rid70">
          70
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8225.html" rel="external">
          "Clinical manifestations of giant cell arteritis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In patients with skeletal muscle vasculitis, the ESR is often, but not always, elevated [
         <a href="#rid64">
          64
         </a>
         ]. Anemia and leukocytosis may be present. Other laboratory findings may reflect the presence of an underlying systemic disorder, such as anti-DNA antibodies in systemic lupus erythematosus, and antineutrophilic cytoplasmic bodies in patients with granulomatosis with polyangiitis and EGPA. Patients with polyarteritis nodosa may have associated hepatitis C or B virus infections.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pathology
         </strong>
         – Histopathologically, vasculitis is identified by the presence of fibrinoid necrosis of the vessel wall in conjunction with transmural inflammation. There may be vascular occlusion in a minority [
         <a href="#rid64">
          64
         </a>
         ]. In all types of systemic vasculitis, macrophages and lymphocytes of various types are commonly noted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In polyarteritis nodosa, neutrophils may be seen within the inflammatory infiltrate, and, with EGPA, eosinophils are common. Giant cells are typically seen in the region of the internal elastic membrane in giant cell arteritis, and they are sometimes seen in other systemic vasculitides. With hypersensitivity vasculitis and vasculitis affecting small blood vessels, fibrinoid necrosis may not be evident, but there should be a transmural inflammatory infiltrate with nuclear debris.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The vast majority of muscle specimens also reveal evidence of neurogenic atrophy. Regenerating and degenerating muscle fibers are also seen in approximately 40 percent of biopsy specimens [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – Treatment depends upon the cause of vasculitis. The treatments are addressed in the individual sections regarding these disorders. (See
         <a class="medical medical_review" href="/z/d/html/8224.html" rel="external">
          "Overview of the management of vasculitis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In isolated peripheral nervous system vasculitis, treatment with glucocorticoids alone is a consideration, but often
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         will be necessary. (See
         <a class="medical medical_review" href="/z/d/html/8221.html" rel="external">
          "Treatment and prognosis of nonsystemic vasculitic neuropathy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a retrospective series that excluded vasculitis associated with inflammatory myopathic conditions, such as polymyositis or dermatomyositis, 33 patients with skeletal muscle vasculitis underwent glucocorticoid therapy, and 19 received additional immunosuppressants [
         <a href="#rid64">
          64
         </a>
         ]. At least 17 (52 percent) improved with combined glucocorticoid and immunosuppressive therapy. Some were lost to follow-up and five died.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H535106583">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Endocrine diseases are generally associated with hormonally mediated systemic alterations in metabolism. Muscle may become affected at any time during the course of several endocrinopathies. The diagnosis of such a myopathy may be more difficult if it is the presenting manifestation of the endocrinopathy. The range of endocrine disorders associated with myopathy includes the following conditions (see
         <a class="local">
          'Endocrine myopathies'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adrenal insufficiency (see
         <a class="local">
          'Adrenal insufficiency'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Cushing syndrome (see
         <a class="local">
          'Cushing syndrome'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diabetes (see
         <a class="local">
          'Diabetic muscle infarction'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hyperaldosteronism (see
         <a class="local">
          'Hyperaldosteronism with myopathy'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hyperparathyroidism (see
         <a class="local">
          'Hyperparathyroid myopathy'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hyperthyroidism (see
         <a class="local">
          'Hyperthyroid myopathy'
         </a>
         above)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Hypothyroidism (see
         <a class="local">
          'Hypothyroid myopathy'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Myopathy is common in osteomalacia. Celiac sprue can present with osteomalacic myopathy. It is important to identify the underlying cause of osteomalacia so that the disorder can be corrected.
         <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">
          Vitamin E
         </a>
         is fat soluble and can be depleted in malabsorption states; a vacuolar myopathy with inflammation can be a consequence, although it is uncommon. (See
         <a class="local">
          'Myopathies associated with malabsorption'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A vacuolar myopathy occurs in patients with repeated bouts of hypokalemic periodic paralysis. Paralysis from severe hypokalemia can also occur in some clinical settings, including chronic diarrhea, renal tubular acidosis, primary aldosteronism, alcoholism, and certain drug and substance intoxications. (See
         <a class="local">
          'Hypokalemic myopathy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the setting of critical illness, the most common causes of neuromuscular weakness are critical illness myopathy (CIM), critical illness polyneuropathy (CIP), or a combination of the two. Risk factors include sepsis, multiorgan failure, and the systemic inflammatory response syndrome. The use of intravenous glucocorticoids is another possible risk factor for CIM. Typical features of CIM and CIP include symmetric, flaccid limb weakness, which is usually worse in proximal compared with distal muscles. Extraocular muscles are relatively spared, and facial muscles are usually but not always spared. (See
         <a class="local">
          'Myopathy associated with critical illness'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The idiopathic inflammatory myopathies dermatomyositis and polymyositis may occur in the setting of systemic connective tissue diseases. Occasionally, skeletal muscle can be affected by amyloidosis, polymyalgia rheumatica (PMR), or vasculitis. (See
         <a class="local">
          'Myopathies in rheumatic diseases'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Thorn GW, Dorrance SS, Day E. Addison's Disease: Evaluation of synthetic desoxycorticosterone acetate therapy in 158 patients. Ann Intern Med 1942; 16:1053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nerup J. Addison's disease--clinical studies. A report fo 108 cases. Acta Endocrinol (Copenh) 1974; 76:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro MS, Trebich C, Shilo L, Shenkman L. Myalgias and muscle contractures as the presenting signs of Addison's disease. Postgrad Med J 1988; 64:222.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harbuz V, Bihan H, Salama J, et al. Flexion contractures possibly reflect the existence of hypocortisolism: two case reports. J Neurol 2010; 257:1129.
          </a>
         </li>
         <li class="breakAll">
          Ruff RL. Endocrine myopathies. In: Myology, Engel AG, Banker BQ (Eds), McGraw Hill, New York 1986. p.1871.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelly FJ, McGrath JA, Goldspink DF, Cullen MJ. A morphological/biochemical study on the actions of corticosteroids on rat skeletal muscle. Muscle Nerve 1986; 9:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith OL, Wong CY, Gelfand RA. Influence of glucocorticoids on skeletal muscle proteolysis in normal and diabetic-adrenalectomized eviscerated rats. Metabolism 1990; 39:641.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Almon RR, Dubois DC. Fiber-type discrimination in disuse and glucocorticoid-induced atrophy. Med Sci Sports Exerc 1990; 22:304.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beato M, Klug J. Steroid hormone receptors: an update. Hum Reprod Update 2000; 6:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reincke M. Cushing Syndrome Associated Myopathy: It Is Time for a Change. Endocrinol Metab (Seoul) 2021; 36:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mitch WE, Bailey JL, Wang X, et al. Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting. Am J Physiol 1999; 276:C1132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           PLOTZ CM, KNOWLTON AI, RAGAN C. The natural history of Cushing's syndrome. Am J Med 1952; 13:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Urbanic RC, George JM. Cushing's disease--18 years' experience. Medicine (Baltimore) 1981; 60:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanco C, Marazuela M, Flores J, Alvarez J. Severe respiratory failure secondary to Cushing's myopathy. J Endocrinol Invest 2001; 24:618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minetto MA, Lanfranco F, Botter A, et al. Do muscle fiber conduction slowing and decreased levels of circulating muscle proteins represent sensitive markers of steroid myopathy? A pilot study in Cushing's disease. Eur J Endocrinol 2011; 164:985.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olafsson E, Jones HR Jr, Guay AT, Thomas CB. Myopathy of endogenous Cushing's syndrome: a review of the clinical and electromyographic features in 8 patients. Muscle Nerve 1994; 17:692.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacomis D, Chad DA, Aronin N, Smith TW. The myopathy of Cushing's syndrome. Muscle Nerve 1993; 16:880.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pleasure DE, Walsh GO, Engel WK. Atrophy of skeletal muscle in patients with Cushing's syndrome. Arch Neurol 1970; 22:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khaleeli AA, Betteridge DJ, Edwards RH, et al. Effect of treatment of Cushing's syndrome on skeletal muscle structure and function. Clin Endocrinol (Oxf) 1983; 19:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berr CM, Stieg MR, Deutschbein T, et al. Persistence of myopathy in Cushing's syndrome: evaluation of the German Cushing's Registry. Eur J Endocrinol 2017; 176:737.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falduto MT, Czerwinski SM, Hickson RC. Glucocorticoid-induced muscle atrophy prevention by exercise in fast-twitch fibers. J Appl Physiol (1985) 1990; 69:1058.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CONN JW, KNOPF RF, NESBIT RM. CLINICAL CHARACTERISTICS OF PRIMARY ALDOSTERONISM FROM AN ANALYSIS OF 145 CASES. Am J Surg 1964; 107:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           RELMAN AS. DIAGNOSIS OF PRIMARY ALDOSTERONISM. Am J Surg 1964; 107:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atsumi T, Ishikawa S, Miyatake T, Yoshida M. Myopathy and primary aldosteronism: electronmicroscopic study. Neurology 1979; 29:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zavatto A, Concistrè A, Marinelli C, et al. Hypokalemic rhabdomyolysis: a rare manifestation of primary aldosteronism. Eur Rev Med Pharmacol Sci 2015; 19:3910.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krishnan AV, Colebatch JG, Kiernan MC. Hypokalemic weakness in hyperaldosteronism: activity-dependent conduction block. Neurology 2005; 65:1309.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clinical conference: Hyperparathyroidism: recent studies. Ann Intern Med 1973; 79:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gutman AB. The differential diagnosis of hyperparathyroidism. JAMA 1934; 103:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           De Luca GC, Eggers SD. A rare complication of azotemic hyperparathyroidism: ischemic calcific myopathy. Neurology 2010; 75:1942.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cholod EJ, Haust MD, Hudson AJ, Lewis FN. Myopathy in primary familial hyperparathyroidism. Clinical and morphologic studies. Am J Med 1970; 48:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           BISCHOFF A, ESSLEN E. MYOPATHY WITH PRIMARY HYPERPARATHYROIDISM. Neurology 1965; 15:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frame B, Heinze EG Jr, Block MA, Manson GA. Myopathy in primary hyperparathyroidism. Observations in three patients. Ann Intern Med 1968; 68:1022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patten BM, Pages M. Severe neurological disease associated with hyperparathyroidism. Ann Neurol 1984; 15:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson ED, Kerrigan K, Butler K, Patel SB. Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy. J Oncol Pharm Pract 2020; 26:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skaria J, Katiyar BC, Srivastava TP, Dube B. Myopathy and neuropathy associated with osteomalacia. Acta Neurol Scand 1975; 51:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Byrne MF, Razak AR, Leader MB, et al. Disabling osteomalacic myopathy as the only presenting feature of coeliac disease. Eur J Gastroenterol Hepatol 2002; 14:1271.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozanoglu E, Basaran S, Goncu MK. Proximal myopathy as an unusual presenting feature of celiac disease. Clin Rheumatol 2005; 24:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hadjivassiliou M, Chattopadhyay AK, Grünewald RA, et al. Myopathy associated with gluten sensitivity. Muscle Nerve 2007; 35:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berger JR. The neurological complications of bariatric surgery. Arch Neurol 2004; 61:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koffman BM, Greenfield LJ, Ali II, Pirzada NA. Neurologic complications after surgery for obesity. Muscle Nerve 2006; 33:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Osteomalacia in a 61-year-old man. Am J Med 1987; 83:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Russell JA. Osteomalacic myopathy. Muscle Nerve 1994; 17:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kleopa KA, Kyriacou K, Zamba-Papanicolaou E, Kyriakides T. Reversible inflammatory and vacuolar myopathy with vitamin E deficiency in celiac disease. Muscle Nerve 2005; 31:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ukaonu C, Hill DA, Christensen F. Hypokalemic myopathy in pregnancy caused by clay ingestion. Obstet Gynecol 2003; 102:1169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rice JE, Faunt JD. Excessive cola consumption as a cause of hypokalaemic myopathy. Intern Med J 2001; 31:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ishikawa S, Kato M, Tokuda T, et al. Licorice-induced hypokalemic myopathy and hypokalemic renal tubular damage in anorexia nervosa. Int J Eat Disord 1999; 26:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharief MK, Robinson SF, Swash M. Hypokalaemic myopathy in alcoholism. Neuromuscul Disord 1997; 7:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taniguchi K, Okino I, Yamamoto N, et al. [Two cases with dropped head syndrome caused by hypokalemic myopathy]. Rinsho Shinkeigaku 2011; 51:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spuler S, Emslie-Smith A, Engel AG. Amyloid myopathy: an underdiagnosed entity. Ann Neurol 1998; 43:719.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simmons Z, Specht CS. The neuromuscular manifestations of amyloidosis. J Clin Neuromuscul Dis 2010; 11:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liewluck T, Milone M. Characterization of isolated amyloid myopathy. Eur J Neurol 2017; 24:1437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muchtar E, Derudas D, Mauermann M, et al. Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome. Mayo Clin Proc 2016; 91:1354.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman Y, Paul JT, Turley J, et al. Axial myopathy due to primary amyloidosis. Muscle Nerve 2007; 36:542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapin JE, Kornfeld M, Harris A. Amyloid myopathy: characteristic features of a still underdiagnosed disease. Muscle Nerve 2005; 31:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gertz MA, Kyle RA. Myopathy in primary systemic amyloidosis. J Neurol Neurosurg Psychiatry 1996; 60:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hull KM, Griffith L, Kuncl RW, Wigley FM. A deceptive case of amyloid myopathy: clinical and magnetic resonance imaging features. Arthritis Rheum 2001; 44:1954.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rubin DI, Hermann RC. Electrophysiologic findings in amyloid myopathy. Muscle Nerve 1999; 22:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada M, Tsukagoshi H, Hatakeyama S. Skeletal muscle amyloid deposition in AL- (primary or myeloma-associated), AA- (secondary), and prealbumin-type amyloidosis. J Neurol Sci 1988; 85:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carr AS, Pelayo-Negro AL, Jaunmuktane Z, et al. Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy. Neuromuscul Disord 2015; 25:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karacostas D, Soumpourou M, Mavromatis I, et al. Isolated myopathy as the initial manifestation of primary systemic amyloidosis. J Neurol 2005; 252:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kojima S, Takagi A, Ida M, Shiozawa R. Muscle pathology in polymyalgia rheumatica: histochemical and immunohistochemical study. Jpn J Med 1991; 30:516.
          </a>
         </li>
         <li class="breakAll">
          Banker B, Engel A. Other inflammatory myopathies. In: Myology, 3rd, Engel AG, Franzini-Armstrong C (Eds), McGraw-Hill, New York 2004. p.1460.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uddhammar A, Rantapää Dahlqvist S, Hedberg B, Thornell LE. Deltoid muscle in patients with polymyalgia rheumatica. J Rheumatol 1998; 25:1344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prayson RA. Skeletal muscle vasculitis exclusive of inflammatory myopathic conditions: a clinicopathologic study of 40 patients. Hum Pathol 2002; 33:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kang Y, Hong SH, Yoo HJ, et al. Muscle Involvement in Polyarteritis Nodosa: Report of Eight Cases With Characteristic Contrast Enhancement Pattern on MRI. AJR Am J Roentgenol 2016; 206:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Panegyres PK, Blumbergs PC, Leong AS, Bourne AJ. Vasculitis of peripheral nerve and skeletal muscle: clinicopathological correlation and immunopathic mechanisms. J Neurol Sci 1990; 100:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savage CO, Winearls CG, Evans DJ, et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med 1985; 56:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ojima Y, Sawada K, Fujii H, et al. Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis (AAV) Restricted to the Limbs. Intern Med 2018; 57:1301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nakamura H, Okada A, Kawakami A, et al. Rheumatoid vasculitis of crural muscles confirmed by muscle biopsy in the absence of inflammatory myopathy: histologic and MRI study. Rheumatol Int 2010; 30:1381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lacomis D, Giuliani MJ, Wasko MC, Oddis CV. Giant cell arteritis presenting with proximal weakness and skeletal muscle vasculitis. Muscle Nerve 1999; 22:142.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5158 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Addison's Disease: Evaluation of synthetic desoxycorticosterone acetate therapy in 158 patients
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4406578" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Addison's disease--clinical studies. A report fo 108 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2845381" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Myalgias and muscle contractures as the presenting signs of Addison's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20157722" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Flexion contractures possibly reflect the existence of hypocortisolism: two case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20157722" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Flexion contractures possibly reflect the existence of hypocortisolism: two case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2419752" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : A morphological/biochemical study on the actions of corticosteroids on rat skeletal muscle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2191192" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Influence of glucocorticoids on skeletal muscle proteolysis in normal and diabetic-adrenalectomized eviscerated rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2199752" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Fiber-type discrimination in disuse and glucocorticoid-induced atrophy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10874567" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Steroid hormone receptors: an update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34139801" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Cushing Syndrome Associated Myopathy: It Is Time for a Change.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10329962" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Evaluation of signals activating ubiquitin-proteasome proteolysis in a model of muscle wasting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12996538" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The natural history of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7453562" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Cushing's disease--18 years' experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11686545" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Severe respiratory failure secondary to Cushing's myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21402749" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Do muscle fiber conduction slowing and decreased levels of circulating muscle proteins represent sensitive markers of steroid myopathy? A pilot study in Cushing's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8196719" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Myopathy of endogenous Cushing's syndrome: a review of the clinical and electromyographic features in 8 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8332144" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The myopathy of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4243379" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Atrophy of skeletal muscle in patients with Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6627703" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Effect of treatment of Cushing's syndrome on skeletal muscle structure and function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28325824" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Persistence of myopathy in Cushing's syndrome: evaluation of the German Cushing's Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2246153" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Glucocorticoid-induced muscle atrophy prevention by exercise in fast-twitch fibers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14099489" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : CLINICAL CHARACTERISTICS OF PRIMARY ALDOSTERONISM FROM AN ANALYSIS OF 145 CASES.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14099490" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : DIAGNOSIS OF PRIMARY ALDOSTERONISM.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/573378" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Myopathy and primary aldosteronism: electronmicroscopic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26531278" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Hypokalemic rhabdomyolysis: a rare manifestation of primary aldosteronism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16247066" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hypokalemic weakness in hyperaldosteronism: activity-dependent conduction block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4748275" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Clinical conference: Hyperparathyroidism: recent studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The differential diagnosis of hyperparathyroidism
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21098411" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : A rare complication of azotemic hyperparathyroidism: ischemic calcific myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5420555" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Myopathy in primary familial hyperparathyroidism. Clinical and morphologic studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14257829" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : MYOPATHY WITH PRIMARY HYPERPARATHYROIDISM.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5646807" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Myopathy in primary hyperparathyroidism. Observations in three patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6732192" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Severe neurological disease associated with hyperparathyroidism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30880569" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Nivolumab-induced hypothyoidism with consequent hypothyroid related myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1119316" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Myopathy and neuropathy associated with osteomalacia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12439125" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Disabling osteomalacic myopathy as the only presenting feature of coeliac disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15349797" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Proximal myopathy as an unusual presenting feature of celiac disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17143894" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Myopathy associated with gluten sensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15313834" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The neurological complications of bariatric surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15973660" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Neurologic complications after surgery for obesity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2821805" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Osteomalacia in a 61-year-old man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8196699" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Osteomalacic myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15389648" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Reversible inflammatory and vacuolar myopathy with vitamin E deficiency in celiac disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14607045" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Hypokalemic myopathy in pregnancy caused by clay ingestion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11512607" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Excessive cola consumption as a cause of hypokalaemic myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10349593" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Licorice-induced hypokalemic myopathy and hypokalemic renal tubular damage in anorexia nervosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9447612" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Hypokalaemic myopathy in alcoholism.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21404610" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : [Two cases with dropped head syndrome caused by hypokalemic myopathy].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9629841" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Amyloid myopathy: an underdiagnosed entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20215989" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : The neuromuscular manifestations of amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28888072" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Characterization of isolated amyloid myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27712634" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Systemic Immunoglobulin Light Chain Amyloidosis-Associated Myopathy: Presentation, Diagnostic Pitfalls, and Outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17405139" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Axial myopathy due to primary amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15478123" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Amyloid myopathy: characteristic features of a still underdiagnosed disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8648333" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Myopathy in primary systemic amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11508448" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : A deceptive case of amyloid myopathy: clinical and magnetic resonance imaging features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10086896" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Electrophysiologic findings in amyloid myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3385435" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Skeletal muscle amyloid deposition in AL- (primary or myeloma-associated), AA- (secondary), and prealbumin-type amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25819286" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15742103" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Isolated myopathy as the initial manifestation of primary systemic amyloidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1798211" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Muscle pathology in polymyalgia rheumatica: histochemical and immunohistochemical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1798211" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Muscle pathology in polymyalgia rheumatica: histochemical and immunohistochemical study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9676767" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Deltoid muscle in patients with polymyalgia rheumatica.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12395371" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Skeletal muscle vasculitis exclusive of inflammatory myopathic conditions: a clinicopathologic study of 40 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26797367" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Muscle Involvement in Polyarteritis Nodosa: Report of Eight Cases With Characteristic Contrast Enhancement Pattern on MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1965205" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Vasculitis of peripheral nerve and skeletal muscle: clinicopathological correlation and immunopathic mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4048389" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Microscopic polyarteritis: presentation, pathology and prognosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29279515" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis (AAV) Restricted to the Limbs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19639318" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Rheumatoid vasculitis of crural muscles confirmed by muscle biopsy in the absence of inflammatory myopathy: histologic and MRI study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9883874" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Giant cell arteritis presenting with proximal weakness and skeletal muscle vasculitis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
